While some companies grab headlines with flashy announcements, others simply execute, quietly benefiting from powerful long-term trends.
These ASX 200 shares may not dominate daily newsfeeds, but they are positioned for durable growth thanks to where the world is headed.
Here are three ASX 200 shares quietly riding major global tailwinds that could reward patient investors.
Goodman Group (ASX: GMG)
Goodman is a global developer of high-spec logistics hubs, urban warehouses, and increasingly, data centre infrastructure. These are all essential to the rise of e-commerce, cloud computing, and artificial intelligence (AI).
What sets Goodman apart is its development pipeline, which is concentrated in data-rich, land-constrained cities like Tokyo, Sydney, and London. This gives it pricing power and long-term growth optionality.
While not as loud as a tech stock, Goodman is a critical enabler of digital infrastructure — and it continues to quietly outperform thanks to its strategic positioning in the backbone of the global economy.
Citi is bullish on its outlook. It currently has a buy rating and $40.00 price target on its shares.
ResMed Inc. (ASX: RMD)
Sleep apnoea may not sound exciting, but this ASX 200 share's leadership in treating it is powering a high-margin global business. Despite short-term noise around GLP-1 weight-loss drugs, ResMed's results remain very strong.
It is capitalising on rising awareness of sleep health, an ageing population, and underdiagnosis in emerging markets. Its tech-enabled platform also gives it a competitive moat, which is turning it into a sticky, recurring revenue machine.
And with the stock still trading below historical valuation multiples, ResMed looks like a top pick for investors right now. Macquarie certainly believes this is the case. It currently has an outperform rating and $48.00 price target on its shares.
Telix Pharmaceuticals Ltd (ASX: TLX)
Finally, Telix could be an ASX 200 share to buy. It is at the forefront of radiopharmaceutical innovation — a field transforming how cancer is diagnosed and treated. With its FDA-approved prostate cancer imaging agent already in market and a pipeline targeting kidney, brain, and other cancers, Telix is building a vertically integrated model with high-value IP and global reach.
Bell Potter is a big fan and believes it is positioned to grow its earnings per share at a compound annual growth rate of 46% over the next two years.
In light of this, the broker has a buy rating and $34.00 price target on its shares.
